Search

814 Result(s)
Sort by

Disentangling fibrosis

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Partnership WHO Foundation mental health

Partnership WHO Foundation mental health

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
IPF why wait?

IPF why wait?

IPF is a progressive and life threatening lung disease that can cause permanent damage in the lungs right from the start. Early diagnosis and treatment of IPF is critical, because acting quickly can make a difference.
Boehringer Ingelheim annouces 2020 BVDzero Case Awards

Boehringer Ingelheim annouces 2020 BVDzero Case Awards

Boehringer Ingelheim is announcing the 2020 ‘BVDzero Case Awards’ are now open for applications. The bi-annual awards reflect the long-term commitment to promoting the health and well-being of farm animals.
It’s Your Heart. Protect It. The Podcast.

It’s Your Heart. Protect It. The Podcast.

In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
sustainably fighting rabies info hub

sustainably fighting rabies info hub

Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
Digital solutions save lives

Digital solutions save lives

Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
BIVF funding more than doubled to 250 M€

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Lyon

Lyon

The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
NEJM-IL-36-Phase-1-GPP-data

NEJM-IL-36-Phase-1-GPP-data

Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
vaxxitek® hvt + ibd + nd

vaxxitek® hvt + ibd + nd

Bursal Disease-Marek's disease-Newcastle disease vaccine, serotype 3, live Marek's disease vector; the vaccine includes a diluent
Access to Healthcare Strategy Innovation

Access to Healthcare Strategy Innovation

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Patient Organizations

Patient Organizations

Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Facts About Asthma

Facts About Asthma

Understand more about what asthma is, how asthma is diagnosed and what you can do to reduce symptoms in your day to day life.